Product How it works Pricing Blog FAQ About Contact
Emergent Biosolutions

Emergent Biosolutions (NYSE: EBS) revenue

Emergent Biosolutions reported revenue of $742.9m for fiscal 2025, 28.8% less than in fiscal 2024 ($1,044m). Since fiscal 2016 its revenue has grown by 52.0%, an average growth of 4.8% a year.

Emergent Biosolutions's revenue has fallen for 4 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −37.0%.

Revenue, in millions of US dollars488.82016560.92017782.420181,10620191,57720201,77420211,11820221,04920231,0442024742.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$742.9m−28.8%$100.1m13.5%
2024$1,044m−0.5%−$108.7m−10.4%
2023$1,049m−6.1%−$726.4m−69.2%
2022$1,118m−37.0%−$170.0m−15.2%
2021$1,774m+12.4%$341.4m19.2%
2020$1,577m+42.6%$438.5m27.8%
2019$1,106m+41.4%$114.1m10.3%
2018$782.4m+39.5%$89.8m11.5%
2017$560.9m+14.8%$124.3m22.2%
2016$488.8m—$105.5m21.6%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Emergent Biosolutions revenue compared with its sector

By revenue for its latest fiscal year, Emergent Biosolutions ranks 172nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Emergent Biosolutions, −28.8%.

RankCompanyRevenueRevenue growth
170thAlphatec$764.2m25.0%
171stiRhythm$747.1m26.2%
172ndEmergent Biosolutions$742.9m−28.8%
173rdRepligen$738.3m16.4%
174thNeoGenomics$727.3m10.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Emergent Biosolutions

How much revenue did Emergent Biosolutions make in fiscal 2025?
Emergent Biosolutions reported revenue of $742.9m for fiscal 2025, compared with $1,044m in fiscal 2024.
How much has the revenue of Emergent Biosolutions grown?
Between fiscal 2016 and fiscal 2025 it went from $488.8m to $742.9m: 52.0% more, an average growth of 4.8% a year.
What was the best year for revenue at Emergent Biosolutions?
Of its last 10 fiscal years, fiscal 2021, with $1,774m.
Where does Emergent Biosolutions rank in its sector by revenue?
It ranks 172nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Emergent Biosolutions come from?
From the annual report (Form 10-K) that Emergent Biosolutions files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Emergent Biosolutions files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Emergent Biosolutions: the Emergent Biosolutions page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.